S.R.I.W.

I-care Group is an industrial company based in Belgium, founded in 2004, that specializes in predictive and prescriptive maintenance services. The company utilizes artificial intelligence and data-driven solutions to enhance the collection and processing of industrial data, enabling clients to anticipate failures in machinery and equipment. By optimizing industrial risk management, I-care Group improves performance across business, human, and environmental dimensions. Its integrated technology expertise and asset management methods help decrease maintenance costs, increase equipment uptime, and enhance overall reliability and safety of operations. The company's focus on delivering high-quality service ensures that clients benefit from improved operational efficiency and effectiveness.

Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

EcoPhos is a Belgian technology provider and leading producer of animal feed phosphates in Europe, headquartered in Louvain-La-Neuve. The company operates with a workforce of 250 employees and includes an engineering office and a demonstration unit. EcoPhos specializes in the manufacturing of inorganic feed phosphates through a process that purifies phosphoric acid and produces various phosphate salts. Its operations focus on delivering agricultural phosphate products that are free from toxic substances, thereby minimizing environmental impact. The company has two production sites with a combined capacity of 300,000 tons per annum, reinforcing its position in the market.

Air Belgium S.A., founded in 1979 and based in Mont-Saint-Guibert, Belgium, provides passenger air transportation services primarily between Brussels and Hong Kong. The airline specializes in offering quality, attractively priced intercontinental flights to selected markets in Asia. Its fleet is equipped with economy, premium, and business class seating options, catering to diverse passenger needs, including provisions for traveling with pets and children. Additionally, Air Belgium enhances the travel experience through onboard catering services, ensuring that passengers enjoy comfortable and pleasant journeys.

Tessares is a Belgian startup founded in 2015, specializing in software that enhances Internet access performance and quality. The company focuses on developing solutions based on Multipath TCP (MPTCP) technology, which allows network operators to combine multiple access technologies, effectively increasing available bandwidth and improving user experience. Tessares’ flagship offering is the Hybrid Access Solution, which creates a more efficient and faster Internet connection without the need for extensive infrastructure investments. The company was established by key developers of the MPTCP protocol and has garnered significant initial funding from Proximus and VIVES. By leveraging its technical expertise, Tessares aims to optimize the Internet experience for clients across various geographic areas.

Qualifio SA, established in 2011 and headquartered in Louvain-La-Neuve, Belgium, operates a Software as a Service (SaaS) platform that enables businesses to engage digital audiences and collect data. The platform facilitates the creation and publication of interactive campaigns, such as quizzes, polls, and contests, across various channels including websites, mobile apps, and social media. Qualifio's solution allows customers to integrate the platform with their existing CRM, DMP, or SSO systems, enabling real-time data collection and segmentation. The company's offerings also extend to increasing registrations and monetizing audiences.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.

Pharmasimple SA is an online retailer specializing in medicines, cosmetics, and food supplements, operating primarily in Belgium and France. The company offers a wide range of beauty and cosmetic products, including face care, makeup, hair treatment, and body care items. Additionally, Pharmasimple provides health products such as feminine hygiene, dental hygiene, alternative medicine, hearing aids, and aromatherapy products. It also caters to men's care needs with face, body, and hair care products, as well as shaving essentials. The company's product range extends to diet and sports nutrition supplements, childcare items like nappies and baby food, and veterinary and pest control products. Founded in 2010 and based in Houdeng-Goegnies, Belgium, Pharmasimple leverages its market presence to negotiate significant discounts with partner laboratories, enabling it to offer competitive prices to customers.

Performance for Assets SA is a Belgium-based company that specializes in developing software for machinery and operations management. The firm offers a data mining and analysis tool designed to assist companies in operations and maintenance by detecting warnings, identifying root causes of machinery failures, and analyzing machine behavior. Its solutions are tailored for industrial manufacturers and wind energy companies, providing a unique approach to optimize and manage process data related to rotating machines. By leveraging a collaborative analytical platform, Performance for Assets converts large data sets into actionable intelligence, enabling clients to effectively manage and enhance critical assets and production processes.

Mydibel is a producer based in Mouscron, Belgium, specializing in a diverse array of potato products. The company offers both deep-frozen and dried options, including classic items like French fries and mashed potatoes, as well as various specialty products that cater to different tastes and preferences. Mydibel's portfolio encompasses fresh, frozen, and dehydrated potato products, ensuring a wide selection for consumers and foodservice businesses alike.

Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, established in 2009. The company specializes in developing and commercializing innovative solutions for treating sleep disordered breathing conditions, particularly moderate to severe obstructive sleep apnea (OSA). Its primary product, the Genio system, is a user-centered, bilateral neurostimulation therapy that has received CE-Mark validation. OSA is a prevalent condition linked to significant health risks, including increased mortality and various comorbidities such as cardiovascular diseases, depression, and stroke. Nyxoah aims to address these critical health challenges through its advanced therapeutic offerings.

Diagenode is an international life sciences company established in 2003 in Liège, Belgium, with a presence in Sparta, New Jersey, and a sales office in the United Kingdom. The company specializes in developing and commercializing advanced instruments and reagent systems for life science research and molecular diagnostics. Diagenode offers a technology platform that includes Bioruptor shearing and IP-Star automation instruments, along with reagent kits and quality antibodies. These products are designed to enhance workflows in epigenetics research, biological sample preparation, and diagnostic assays, serving a diverse clientele that includes prominent epigenetics researchers, academic institutions, genome centers, core laboratories, and pharmaceutical and biotechnology companies.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

Decube Group is a company based in Strépy-Bracquegnies, Belgium, specializing in technical and industrial services, including engineering, assembly, and industrial painting. The company focuses on providing solutions that help clients prevent corrosion and modify the surface of manufactured parts to achieve specific aesthetic and functional requirements. By offering a range of services under one roof, Decube enables its clients to streamline their operations and maintain the quality and appearance of their products.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that focuses on inventing and developing small molecule drugs that target G-Protein Coupled Receptors (GPCRs). The company's lead product, fezolinetant, is currently in Phase II clinical development for treating women's health disorders. In addition to fezolinetant, Ogeda is developing other small molecules aimed at addressing various therapeutic areas, including inflammatory and autoimmune diseases. Founded in 1994 and formerly known as Euroscreen, Ogeda operates additional facilities in Brussels, Belgium, and Paris, France. The company is a subsidiary of Astellas Pharma Inc. and is supported by prominent investors in the biotechnology sector.

CluePoints Inc. is a company that specializes in developing cloud-based software for risk-based quality management and monitoring, primarily serving pharmaceutical companies and contract research organizations (CROs). Founded in 2012 and headquartered in King of Prussia, Pennsylvania, with an additional office in Louvain-la-Neuve, Belgium, CluePoints offers solutions designed to identify, visualize, manage, and document risks associated with clinical trials. Its flagship product utilizes advanced statistical algorithms to assess the quality, accuracy, and integrity of clinical trial data both during and after studies. By adhering to guidelines from regulatory bodies such as the ICH, FDA, and EMA, CluePoints supports traditional on-site monitoring and medical reviews while driving effective risk-based monitoring strategies. The software is notable for its ability to detect anomalous data and site errors, ultimately enhancing clinical data quality, optimizing on-site monitoring efforts, and reducing the risks associated with regulatory submissions.

ChanvrEco S.A., founded in 2007 and based in Tinlot, Belgium, specializes in the manufacture of standard granulate derived from hemp straw, primarily for use in thermal and acoustic insulation. The company's flagship product, Prohemp, is an aggregate made from hemp that is specifically designed for building insulation applications. ChanvrEco serves the construction industry, contributing to sustainable building practices through its eco-friendly materials.

Fruytier Group is a prominent player in the European softwood processing industry, involved in every stage of the timber supply chain, from sourcing round wood to delivering finished products. The company specializes in providing sawn wood for various applications, including structures, packaging, siding, and outdoor decking, primarily using Spruce and Douglas Fir sourced from local, sustainable timber resources. In addition to sawn wood, Fruytier Group supplies sawmill by-products such as pellets, sawdust, chips, and bark. Its services encompass sawing and grading, high-precision re-cutting, drying, planing, moulding, and treatment processes like dipping and high-pressure impregnation. Positioned in the heart of Europe, Fruytier Group efficiently processes over 1 million cubic meters of timber annually across its facilities in Belgium, Germany, and France, ensuring high-quality products with quick turnaround times for its partners in sectors such as prefabricated housing and retail.

Trendy Foods Belgium is a distributor of a diverse range of food products, primarily focusing on confectionery items. The company serves Belgium and other European markets, providing an extensive selection that includes beverages, frozen foods, soft drinks, alcoholic beverages, flowers, plants, seasonal items, and fruits. This broad assortment enables customers to select from a variety of desired products, catering to different tastes and preferences.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.

Lampiris N.V., founded in 2003 and based in Liège, Belgium, is an independent supplier of electricity and gas, serving both private individuals and businesses. The company has been active in the Belgian energy market since 2005 and has established itself as the third-largest supplier in the residential sector, with over a million accounts. In addition to energy supply, Lampiris offers various energy services, including insulation, furnace maintenance, and heating solutions using wood and pellets, as well as smart thermostats. As of September 2016, Lampiris operates as a subsidiary of Elf Aquitaine S.A.

KitoZyme S.A. is a biotechnology company based in Herstal, Belgium, specializing in the development and production of biopolymers derived from non-animal sources, particularly chitosan and chitin-glucan. The company serves various markets, including nutraceuticals, cosmetics, beverages, and pharmaceuticals. In the nutraceutical sector, KitoZyme offers products such as KiOnutrime-Cs for weight management and KiOnutrime-CG for oxidative stress management. Its cosmetic line features KiOsmetine-CG, a multifunctional ingredient for skin care, and KiOsmetine-S, a plant-based alternative to silicone. For the beverage industry, KitoZyme provides KiOfine-CG, a fining agent for wines, and KiOfine-B, a processing aid for contaminant removal. In pharmaceuticals, it develops KiOmedine for applications in wound management and drug delivery systems. KitoZyme's commitment to innovation is supported by scientifically proven technologies, and it distributes its products through partners across multiple countries, including the United States and various European nations.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that focuses on inventing and developing small molecule drugs that target G-Protein Coupled Receptors (GPCRs). The company's lead product, fezolinetant, is currently in Phase II clinical development for treating women's health disorders. In addition to fezolinetant, Ogeda is developing other small molecules aimed at addressing various therapeutic areas, including inflammatory and autoimmune diseases. Founded in 1994 and formerly known as Euroscreen, Ogeda operates additional facilities in Brussels, Belgium, and Paris, France. The company is a subsidiary of Astellas Pharma Inc. and is supported by prominent investors in the biotechnology sector.

iTeos Therapeutics is a biopharmaceutical company dedicated to developing immuno-oncology therapies for cancer patients. Founded in 2011, the company operates from headquarters in Cambridge, Massachusetts, and Gosselies, Belgium. iTeos focuses on discovering and advancing small molecule immunomodulators that target the tumor microenvironment, aiming to enhance the body's immune response against cancer. Its pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor, and EOS-448, an antagonist of TIGIT, both currently in Phase 1/2a clinical trials. iTeos' approach is built on the expertise of Ludwig Cancer Research, aiming to improve clinical outcomes by restoring the immune system's ability to fight cancer.

Dragone is a creative company based in La Louviere, Belgium, specializing in the production of theatrical performances. The company operates customized theaters designed to enhance the audience's experience and hosts a variety of artistic events, including ballet and opera. In addition to organizing these entertainment shows, Dragone is involved in the design of costumes and the writing of stories, effectively merging human talent, artistic disciplines, and technical innovations to bring captivating narratives to life. Through its diverse offerings, Dragone aims to create memorable experiences for audiences.

Rentel, a Belgian company, specializes in offshore wind energy. It develops, finances, constructs, and operates offshore wind parks in the Belgian North Sea, with potential expansion abroad.

Alysse Food S.A. is a bakery company based in Seneffe, Belgium, specializing in the production of American-style baked goods, including bagels, muffins, brownies, and cupcakes. Established in 1995, Alysse Food operates in Brussels and functions as a subsidiary of Patisseries Gourmandes SA. The company is focused on delivering high-quality bakery products to meet consumer demands in the market.

Xylowatt S.A. is a Belgian company based in Louvain-La-Neuve that focuses on developing gasification reactors to convert biomass and waste products into renewable energy. Founded in 2001, the company specializes in its NOTAR technology, which allows for energy production from a variety of contaminated residues, including different types of wood waste and sewage sludge. Xylowatt also offers oxy-gasification solutions and expert services, catering to engineering, procurement, and construction (EPC) contractors, industrial customers, and research and development departments. The company's industrial gasifiers are designed to produce clean syngas without tar residues, integrating cogeneration engines to convert wood chips into valuable energy, thereby enabling clients to benefit from locally sourced green energy. Xylowatt operates as a subsidiary of Icafin SA/NV.

CISSOID S.A. specializes in manufacturing high-temperature semiconductor solutions tailored for power management, power conversion, and signal conditioning in extreme environments. The company offers a range of products, including voltage regulators, voltage references, power switches, diodes, transistors, and high-voltage silicon carbide power modules. Their integrated circuits are designed to operate reliably in temperatures ranging from -55°C to +225°C, with testing extending from -200°C to +300°C. CISSOID's offerings also include mixed signal ICs, such as analog-to-digital converters and amplifiers, as well as high-temperature packaging and electronic systems design services. The company serves various markets, including oil and gas, aerospace, industrial, and automotive sectors, through a network of distributors and representatives across multiple regions, including Asia-Pacific, Europe, and the Americas. Established in 2000 and based in Mont Saint Guibert, Belgium, CISSOID has developed a reputation for reliability through its extensive experience in silicon technologies and high-temperature applications.

Viridaxis SA is a biotechnology company based in Charleroi, Belgium, specializing in the development of biological solutions for horticulturalists and farmers. Founded in 2004 as a spin-off from Louvain Catholic University, the company focuses on the mass production of beneficial insects, particularly parasitoids, to combat crop pests. Utilizing innovative technology, Viridaxis produces environmentally friendly products that serve as alternatives to toxic insecticides, employing biopolymer capsules filled with powdered crustacean and algae extracts. The company supplies its products to both Belgian and multinational companies in the agricultural sector, while expanding its research and development activities to enhance production capacity and develop new offerings.

Advanced Biological Laboratories (ABL) is a medical data technology company founded in 2000, specializing in healthcare management products for data and patient management, monitoring, and personalized reporting applications. ABL offers a suite of products such as Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC®, and the DPM. These products are utilized by infectious disease clinicians and virology laboratories to provide optimal and efficient IT solutions for sequencing, clinical genotyping, and drug resistance analysis. Some of ABL's products have received CE-marking for IVD use, and the upcoming data processing module is an FDA registered class I medical device. ABL also acquired TherapyEdge, Inc. in 2004 and the rights to viral hepatitis B & C related assets from EVIVAR MEDICAL in 2013.